Bone and connective tissue cancer:
Indications for: TAZVERIK
Metastatic or locally advanced epithelioid sarcoma in patients not eligible for complete resection.
Adult Dosage:
Swallow whole. ≥16yrs: 800mg twice daily; continue until disease progression or unacceptable toxicity. Dose modifications for adverse reactions or for drug interactions: see full labeling.
Children Dosage:
<16yrs: not established.
TAZVERIK Warnings/Precautions:
Increased risk of secondary malignancies (eg, myelodysplastic syndrome, acute myeloid leukemia, T-cell lymphoblastic lymphoma). Embryo-fetal toxicity. Advise to use effective contraception (non-hormonal) during and for 6 months (females of reproductive potential) and for 3 months (males w. female partners) after the last dose. Pregnancy: exclude status prior to initiation. Nursing mothers: not recommended (during and for 1 week after the last dose).
TAZVERIK Classification:
Methyltransferase inhibitor.
TAZVERIK Interactions:
May be potentiated by strong or moderate CYP3A inhibitors; avoid. If concomitant use with moderate CYP3A inhibitors is unavoidable, reduce dose (see full labeling). May be antagonized by strong or moderate CYP3A inducers; avoid. May antagonize CYP3A substrates, including hormonal contraceptives.
Adverse Reactions:
Pain, fatigue, nausea, decreased appetite, vomiting, constipation, upper RTI, musculoskeletal pain, abdominal pain; lab abnormalities.
Generic Drug Availability:
NO
How Supplied:
Tabs—240
Leukemias, lymphomas, and other hematologic cancers:
Indications for: TAZVERIK
Relapsed or refractory follicular lymphoma in patients whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, or in patients with no satisfactory alternative treatment options.
Adult Dosage:
Confirm presence of EZH2 mutation of codons Y646, A682, or A692 in tumor specimens. Swallow whole. ≥16yrs: 800mg twice daily; continue until disease progression or unacceptable toxicity. Dose modifications for adverse reactions or for drug interactions: see full labeling.
Children Dosage:
<16yrs: not established.
TAZVERIK Warnings/Precautions:
Increased risk of secondary malignancies (eg, myelodysplastic syndrome, acute myeloid leukemia, T-cell lymphoblastic lymphoma). Embryo-fetal toxicity. Advise to use effective contraception (non-hormonal) during and for 6 months (females of reproductive potential) and for 3 months (males w. female partners) after the last dose. Pregnancy: exclude status prior to initiation. Nursing mothers: not recommended (during and for 1 week after the last dose).
TAZVERIK Classification:
Methyltransferase inhibitor.
TAZVERIK Interactions:
May be potentiated by strong or moderate CYP3A inhibitors; avoid. If concomitant use with moderate CYP3A inhibitors is unavoidable, reduce dose (see full labeling). May be antagonized by strong or moderate CYP3A inducers; avoid. May antagonize CYP3A substrates, including hormonal contraceptives.
Adverse Reactions:
Pain, fatigue, nausea, decreased appetite, vomiting, constipation, upper RTI, musculoskeletal pain, abdominal pain; lab abnormalities.
Generic Drug Availability:
NO
How Supplied:
Tabs—240
